Sign in
CompletedNo phase

Laser Therapy in Women With Lichenoid Disorders

Key facts

Who runs it
Medical University of Graz
Where
Austria1 site in 1 countryChoose a country to see its sites
Trial code
Status
Completed
People taking part
40 people enrolled
Started
17 Nov 2020
Ended
13 Jun 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Laser
  • Placebolaser
Record updated
13 May 2025

Who can take part

Age
18 years to 99 years
Sex
Women only
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 26 criteriaShow less

Who can take part

  • women age >18 years
  • diagnosed with LD (VLS or LP histologically proven)
  • Clinical LS score ≥ 4 based on the score of Günthert et al. [1]
  • Normal Pap-smear within 24 months
  • negative clinical and microscopic evaluation of vaginal fluid
  • Negative test for STD (sexually transmitted diseases) pathogens (chlamydia, gonorrhea, genital mycoplasma and trichomonas) if symptomic including abdominal pain or abnormal vaginal fluid
  • Good German language skills
  • written informed consent
  • preceding local corticoid therapy of at least 12 weeks according to the current guideline for LD

Who cannot take part

  • patients who have undergone any kind of organ transplantation in the last three years
  • any vulvar/ vaginal infection
  • genital malignant disease
  • allergy to topical anaesthesia
  • connective tissue disease
  • History of transvaginal mesh implant (excluding sling or sacrocolpopexy mesh)
  • patients with renal, hepatic or pulmonary-cardiovascular failure
  • women with contraindications for the use of laser on the skin
  • pregnancy
  • presence of vulvar pathology (other than lichen)
  • immunocompromised women
  • swollen lymph nodes
  • keloid formation
  • Patients with a legal guardian
  • Body Mass Index > 35 kg/m²
  • Coagulopathy
  • patients using anticoagulants

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Primary aim of the trial is to compare improvement of lichen symptoms according to a composite VAS scale (burning, itching and pain) between women with vulvovaginal laser therapy vs. sham laser therapy at three months.

The 2 groups in the trial

  • LaserExisting treatment, for comparison

    Before treatment the vulva will be carefully inspected to rule out signs of infection or recent trauma. A local anesthetic cream (Emla cream 5%) will be applied to the entire introitus vulvae and all areas intended for local laser treatment. Before laser treatment another cotton swab test will be performed to ensure sufficient local anesthesia. Vulvovaginal laser therapies will be performed with the non-ablative 2940 nm Er:YAG laser (Smooth XS, Fotona, Slovenia) in the Renova mode according to the manufacturer's guidelines and recommendations. The spot size (diameter of the laser beam) is 7 mm, with a pulse at a frequency of 1.6 Hz, and a fluence (laser energy delivered per unit area) of 5.0 to 10.0 J/cm2. The vulva will be treated using 1-3 repetitions.

  • Placebo LaserPlacebo, for comparison

    Clinical examination and preparations will be identical to the intervention group. Sham laser treatments will be performed with the same laser and the same device. However, a specially designed placebo probe, which blocks the emission of radiation, will be used. Women will therefore receive no therapeutic laser treatment. Before treatment, a study assistant, who is aware of the study allocation, will prepare the laser with the placebo probe, which looks identically to the "normal" probe. The treating physician will not be aware of the study allocation and the type of probe in use.

    Treatment: Placebolaser

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Laser Therapy in Women With Lichenoid Disorders: A Randomized Controlled Trial
Record updated
13 May 2025